SLC5A2 and type 2 diabetes mellitus: In patients with T2D, 2 weeks of treatment with SGLT2 inhibition enhanced peripheral glucose disposal but also increased EGP rate.30 While it has been proposed that this may reflect the amelioration of glucotoxicity as a consequence of renal glucose loss and the consequent improvement in glycemic control, the precise mechanisms underpinning this observation remain to be determined.